Demand for human leukocyte antigen or human platelet antigen‐selected platelets: An observational study at Canadian Blood Services
Transfusion · 2026
DOI: 10.1111/trf.70025 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Transfusion, 2026. Verfasst von Natasha Rickards und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Affairs Division, Canadian Blood Services, Ottawa, Canada. Hauptthemen laut MEDLINE: Platelet Transfusion, HLA Antigens, Antigens, Human Platelet, Blood Platelets. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Blood Services.
Abstract (Originalsprache)
Background
Platelet transfusion refractoriness (PTR) is a clinically important condition. The Human Leukocyte Antigen and Human Platelet Antigen (HLA/HPA) Platelet Program at Canadian Blood Services (CBS) provides platelet products to support such patients. This study provides a blood operator perspective on the provision of products for the management of immune‐mediated PTR (iPTR), including the evaluation of patient data to determine trends in the prevalence and diagnoses associated with iPTR. Study design and methods A retrospective observational study of patients enrolled in the CBS HLA/HPA Platelet Program between April 2021 and March 2025. Patient demographics and platelet product issuance were extracted from internal electronic records. Descriptive statistics were utilized for baseline characteristics and linear regression for temporal trends.
Results
We identified 788 cases representing 688 unique patients. Median patient age was 60.5 years. The most frequent diagnoses were acute leukemia (44%) and myelodysplastic syndrome (15%). HLA/HPA platelet issuance showed a statistically significant upward trend (average increase 23 units/quarter, p = .004). Platelet requests strongly predicted units issued ( R 2 = 0.92, p < .001), whereas the number of cases was a weak predictor for the number of platelets issued.
Discussion
The CBS HLA/HPA Platelet Program has experienced a rise in product demand. The strong relationship between product requests and issuance demonstrates the responsiveness of this program, though variability in fill rates and the limited predictive value of case counts highlight ongoing operational challenges. These findings can inform strategies for donor recruitment, inventory management, and case management to ensure reliable access to compatible platelets for sensitized patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Affairs Division, Canadian Blood Services, Ottawa, Canada.
- Cancer Research Program, Ottawa Hospital Research Institute, Ottawa, Canada.
- Division of Hematology, Department of Medicine, McGill University Health Center, Montreal, Canada.
- Division of Hematology, Department of Medicine, University of British Columbia, Vancouver, Canada.
- Dalhousie University, Halifax, Canada.
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada.
ORCID-Profile: Phuoc-An Duong Hoang
Förderung
- Canadian Blood Services
Zitieren
APA
Rickards, N., Hoang, P. D., Mack, J., Seftel, M., Blake, J. T., & Gupta, A. (2026). Demand for human leukocyte antigen or human platelet antigen‐selected platelets: An observational study at Canadian Blood Services. Transfusion. https://doi.org/10.1111/trf.70025
Vancouver
Rickards N, Hoang PD, Mack J, Seftel M, Blake JT, Gupta A. Demand for human leukocyte antigen or human platelet antigen‐selected platelets: An observational study at Canadian Blood Services. Transfusion. 2026. doi:10.1111/trf.70025
BibTeX
@article{Rickards2026,
author = {Rickards, Natasha and Hoang, Phuoc-An Duong and Mack, Johnathan and Seftel, Matthew and Blake, John T and Gupta, Akash},
title = {Demand for human leukocyte antigen or human platelet antigen‐selected platelets: An observational study at Canadian Blood Services},
journal = {Transfusion},
year = {2026},
doi = {10.1111/trf.70025}
}
EUVIMED